Idorsia Pharmaceuticals Ltd.

Quick facts

Phase 3 pipeline

• ACT-129968 · Neurology / Sleep Medicine
  ACT-129968 is a selective orexin 2 receptor antagonist that promotes sleep by blocking wake-promoting signals in the brain.

Phase 2 pipeline

• ACT-539313 · Psychiatry
  ACT-539313 is a selective dopamine D2 receptor antagonist.
• ACT-541468 · Sleep disorders
  ACT-541468 is a selective orexin receptor antagonist.
• ACT-709478 for oral use · Psychiatry
  ACT-709478 is a selective dopamine receptor D2/D3 antagonist.

Phase 1 pipeline

• AC-082
• AC-083
• ACT-1004-1239
• ACT-1014-6470
• ACT-132577
• ACT-389949 200 mg
• ACT-451840:
• ACT-451840 1000 mg
• ACT-451840 200 mg
• ACT-709478
• ACT-709478 combined with midazolam
• ACT541468
• ID-082
• ID-085

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Idorsia Pharmaceuticals Ltd. portfolio CI brief
• Idorsia Pharmaceuticals Ltd. pipeline updates RSS